Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.
Level 5 - mechanism / opinion, no new human data
In vitro pharmacological signaling and primary islet bench study
PubMed 32730231 · doi:10.1172/jci.insight.140532
What was done
The authors calculated receptor occupancy for tirzepatide at glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors at clinically relevant doses. They evaluated signaling pathways (cAMP generation, beta-arrestin recruitment, receptor internalization) compared to native peptides, and assessed insulin secretion mechanisms in primary islets.
What was found
No quantitative numbers are reported in the abstract. Tirzepatide demonstrated higher receptor occupancy for GIP receptors than GLP-1 receptors. At the GIP receptor, it mimicked native GIP activity, whereas at the GLP-1 receptor, it exhibited biased agonism favoring cAMP generation over beta-arrestin recruitment, with reduced receptor internalization compared to native GLP-1. In primary islets, beta-arrestin1 limited the insulinotropic response to native GLP-1, but not to GIP or tirzepatide.
Why it matters
This study provides a molecular mechanism for tirzepatide's metabolic efficacy, showing it functions via imbalanced GIP receptor engagement and biased GLP-1 receptor signaling to enhance insulin secretion.
Limits
The study is limited to in vitro signaling assays, computational occupancy models, and primary islet experiments. No human clinical outcomes, sample sizes, or in vivo pharmacokinetic parameters are reported in the abstract.
Cited by
- supports Tirzepatide has an approximate 1 to 5 ratio of GLP-1 receptor to GIP receptor activity.